Floatz logo

TEONANACATL

Cancer of Endometrium

Psyence Australia Pty LtdSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Cancer of Endometrium cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BBB
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
Eli Lilly and Company
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 3BB
Carboplatin
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

TEONANACATL is also rated in:

major depressive disorderDormant
BB
Indicative ·
70 / 100
View asset →
depressive disorderDormant
BB
Indicative ·
69 / 100
View asset →
bipolar II disorderDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →